Regular Article

British Journal of Cancer (2001) 84, 897–902. doi:10.1054/bjoc.2001.1703 www.bjcancer.com
Published online 3 April 2001

Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women

M B Marttunen1, B Cacciatore1, P Hietanen2, S Pyrhönen2, A Tiitinen1, T Wahlström3 and O Ylikorkala1

  1. 1Departments of Obstetrics and Gynecology, Helsinki University Central Hospital, P.O. Box 140, FIN-00029 HYKS, Finland
  2. 2Department of Oncology, Helsinki University Central Hospital, P.O. Box 180, FIN-00029 HYKS, Finland
  3. 3Department of Pathology, Helsinki University Central Hospital, P.O. Box 140, FIN-00029 HYKS, Finland

Received 3 April 2000; Revised 19 December 2000; Accepted 19 January 2001.

Top

Abstract

To assess and compare the gynaecological consequences of the use of 2 antioestrogens we examined 167 postmenopausal breast cancer patients before and during the use of either tamoxifen (20 mg/day, n = 84) or toremifene (40 mg/day, n = 83) as an adjuvant treatment of stage II–III breast cancer. Detailed interview concerning menopausal symptoms, pelvic examination including transvaginal sonography (TVS) and collection of endometrial sample were performed at baseline and at 6, 12, 24 and 36 months of treatment. In a subgroup of 30 women (15 using tamoxifen and 15 toremifene) pulsatility index (PI) in an uterine artery was measured before and at 6 and 12 months of treatment. The mean (plusminusSD) follow-up time was 2.3 plusminus 0.8 years. 35% of the patients complained of vasomotor symptoms before the start of the trial. This rate increased to 60.0% during the first year of the trial, being similar among patients using tamoxifen (57.1%) and toremifene (62.7%). Vaginal dryness, which was present in 6.0% at baseline, increased during the use of tamoxifen (26.2%) and toremifene (24.1%). Endometrial thickness increased from baseline (3.9 plusminus 2.7 mm) to 6.8 plusminus 4.2 mm at 6 months (P< 0.001), and no difference emerged between the 2 regimens in this regard. Before the start of the antioestrogen regimen, the endometrium was atrophic in 71 (75.5%) and proliferative in 19 of 94 (20.2%) samples; 4 patients had benign endometrial polyps. During the use of antioestrogen altogether 339 endometrial samples were taken (159 in tamoxifen group, 180 in toremifene group). The endometrium was proliferative more often in the tamoxifen group (47.8%) than in the toremifene group (32.2%) (P< 0.0001). 20 patients had a total of 24 polyps (17 in tamoxifen and 9 in toremifene group, P< 0.05) during the use of antioestrogens. One patient in the toremifene group developed endometrial adenocarcinoma at 12 months, and one patient had breast cancer metastasis on the endometrium. Tamoxifen failed to affect the PI in the uterine artery, but toremifene reduced it by 15.0% (P< 0.05) by 12 months. In conclusion, tamoxifen and toremifene cause similarly vasomotor and vaginal symptoms. Neither regimen led to the development of premalignant endometrial changes. Our data suggest that so close endometrial surveillance as used in our study may not be mandatory during the first 3 years of use of antioestrogen treatment. © 2001 Cancer Research Campaign

Keywords:

breast cancer, antioestrogens, tamoxifen, toremifene, endometrium

Top

References

  1. Adami H-O, Bergström R, Weiderpass E, Persson I, Barlow L and McLaughlin JK (1997) Risk for endometrial cancer following breast cancer: a prospective study in Sweden. Cancer Causes Control 8: 821–827
  2. Barakat RR (1996) Tamoxifen and endometrial neoplasia. Clin Obstet Gynecol 39: 629–640 | PubMed |
  3. Buckley MMT and Goa KL (1989) Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs 37: 451–490 | PubMed | ChemPort |
  4. Cacciatore B, Paakkari I, Toivonen J, Tikkanen MJ and Ylikorkala O (1998) Randomized comparison of oral and transdermal hormone replacement on the carotid and uterine artery resistance to blood flow. Obstet Gynecol 92: 563–568
  5. Chambers JT and Chambers SK (1992) Endometrial sampling: When? Where? Why? With what? Clin Obstet Gynecol 35: 28–39
  6. Cohen I, Rosen DJD, Tepper R, Cordoba M, Altaras MM and Byeth Y (1993) Ultrasonographic evaluation of the endometrium and correlation with endometrial sampling in postmenopausal patients treated with tamoxifen. J Ultrasound Med 5: 275–280
  7. Cohen I, Altaras MM, Lew S, Tepper R, Beyth Y and Ben-Baruch G (1994) Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy: A case report and review of the literature. Gynecol Oncol 55: 443–447 | Article | PubMed | ISI | ChemPort |
  8. Di Salle E, Zaccheo T and Ornati G (1990) Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat. J Steroid Biochem 36: 203–206
  9. Early Breast Cancer Trialists' Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451–1467 | Article | PubMed | ISI |
  10. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL and Cronin WM (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86: 527–537 | Article | PubMed | ChemPort |
  11. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E and Ford L Wolmark N and other investigators of NSABBP (1998) Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371–1388 | Article | PubMed | ChemPort |
  12. Fornander T, Hellström A-C and Moberger B (1993) Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst 85: 1850–1855
  13. Friedl A and Jordan VG (1994) What do we know and what don't we know about tamoxifen in the human uterus. Breast Cancer Res Treat 31: 27–39
  14. Garfinkel L, Boring CC and Heath, Jr. CW (1994) Changing trends. An overview of breast cancer incidence and mortality. Cancer 74: 222–227
  15. Goldstein SR (1994) Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol 170: 447–451 | PubMed | ISI | ChemPort |
  16. Hayes DF, Van Zyl JA, Hacking A, Goedhals L, Bezwoda WR, Mailliard JA, Jones SE, Vogel CL, Berris RF, Shemano I and Schoenfelder J (1995) Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 13: 2556–2566
  17. Hillard TC, Bourne TH, Whitehead MI, Crayford TB, Collins WP and Campbell S (1992) Differential effects of transdermal estradiol and sequential progestogens on impedance to flow within the uterine arteries of postmenopausal women. Fertil Steril 58: 959–963
  18. Holli K (1998) Adjuvant trials of toremifene vs tamoxifen: The European experience. Oncology 12: 23–27 | PubMed | ISI | ChemPort |
  19. Ismail SM (1996) The effects of tamoxifen on the uterus. Current Opin Obstet Gynecol 8: 27–31
  20. Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO and Campbell S (1994) Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 343: 1318–1321
  21. Lahti E, Blanco G, Kauppila A, Apaja-Sarkkinen M, Taskinen PJ and Laatikainen T (1993) Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 81: 660–664
  22. Love R, Cameron L, Connell BL and Leventhal H (1991) Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 151: 1842–1847 | PubMed |
  23. McGonigle KF, Shaw SL, Vasilev SA, Odom-Maryon T, Roy S and Simpson JF (1998) Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy. Am J Obstet Gynecol 178: 1145–1150
  24. Neven P (1995) Endometrial changes in patients on tamoxifen. Lancet 346: 1292
  25. Pirhonen JP, Vuento MH, Mäkinen JI and Salmi TA (1993) Long-term effects of hormone replacement therapy on the uterus and on uterine circulation. Am J Obstet Gynecol 168: 620–623
  26. Pyrhönen S, Ellme'n J, Vuorinen J, Gershanovich M, Tominaga T, Kaufman M and Hayes DF (1999) Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breas cancer. Breast Cancer Res Treat 56: 133–143 | PubMed |
  27. Ribeiro G and Swindell R (1988) The Christie hospital adjuvant tamoxifen trial: Status at 10 years. Br J Cancer 57: 601–603
  28. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander H and Wilking N (1995) Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 87: 645–651 | Article | PubMed | ChemPort |
  29. Stewart HJ, Forrest AP, Everington D, McDonald CC, Dewar JA, Hawkins RA, Prescott RJ and George WD (1996) Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer: the Scottish Cancer Trials Breast Group. Br J Cancer 74: 297–299 | PubMed |
  30. Tesoro MR, Borgida AF, Maclaurin NA and Asuncion CM (1999) Transvaginal endometrial sonography in postmenopausal women taking tamoxifen. Obstet Gynecol 93: 363–366
  31. Tomás E, Kauppila A, Blanco G, Apaja-Sarkkinen M and Laatikainen T (1995) Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol Oncol 59: 261–266 | PubMed | ChemPort |
  32. Touraine P, Driguez P, Cartier I, Yaneva H, Kuttenn F and Mauvais-Jarvis P (1995) Lack of induction of endometrial hyperplasia with tamoxifen. Lancet 345: 254–255
  33. van Leeuwen FE, Benraadt J, Coebergh JWW, Kiemeney LALM and Gimbre're CHF (1994) Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343: 448–452 | Article | PubMed | ChemPort |
  34. Widrich T, Bradley LD, Mitchinson AR and Collins RI (1996) Comparison of saline infusion sonography with office hysteroscopy for the evaluation of the endometrium. Am J Obstet Gynecol 174: 1327–1334
  35. Wiseman LR and Goa KL (1997) Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer. Drugs 54: 141–160 | PubMed | ChemPort |